A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease Public Deposited
- Creator
- Desai, Payal C.
- Brittain, Julia E.
- Jones, Susan K.
- McDonald, Adam
- Wilson, Douglas R.
- Dominik, Rosalie
- Key, Nigel S.
- Parise, Leslie V.
- Ataga, Kenneth I.
- Abstract
- The contribution of platelet activation to the pathogenesis of sickle cell disease (SCD) remains uncertain. We evaluated the safety and efficacy of eptifibatide, a synthetic peptide inhibitor of the αIIbβ3 receptor, in SCD patients during acute painful episodes.
- Date of publication
- 2013
- Keyword
- confidence intervals
- patient controlled analgesia
- Safety
- sickle cell disease
- Pilot Projects
- Adolescent
- Platelet Activation
- Male
- Humans
- PCA
- Acute Pain
- Sickle cell disease
- Acute painful episode
- CD40 ligand
- CD40L
- Middle Aged
- Female
- Platelet activation
- Peptides
- Eptifibatide
- Adult
- Anemia, Sickle Cell
- Double-Blind Method
- SCD
- CI
- DOI
- Identifier
- PMID: 23973010
- Onescience id: e229cc39d52e3c1d2336daadf8c8162494b8fd76
- Publisher DOI: https://doi.org/10.1016/j.thromres.2013.08.002
- PMCID: PMC3791139
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- Thrombosis Research
- Journal volume
- 132
- Journal issue
- 3
- Page start
- 341
- Page end
- 345
- Language
- English
- ISSN
- 1879-2472
- 0049-3848
- Parents:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
EuropePMC-PMC3791139.pdf | 2020-11-01 | Public |
|